Given the critical role of RBM39 in tumorigenesis, a small molecule (indisulam) that targets and degrades RBM39 has been found to be an effective treatment for HCC and other tumor types (Nijhuis et al, 2022; Xu et al, 2021). Here, RBM39 is linked to hepatocellular carcinoma.